SER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Serina Therapeutics Inc (SER) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company is in the early stages of clinical trials for its key drug, SER-252, and while this could be a positive catalyst in the future, the current financial performance and technical indicators do not support a strong entry point. Additionally, there are no significant trading trends or proprietary trading signals to suggest immediate action.
The technical indicators show a bearish trend with the MACD histogram below 0 and negatively contracting, RSI in the neutral zone at 48.111, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point (1.749) with resistance at 1.931 and support at 1.567, indicating limited upside potential in the short term.
The company has dosed its first patient in a Phase 1b clinical trial for SER-252, targeting advanced Parkinson's disease. The FDA has approved the Investigational New Drug application for SER-252, and partnerships with Parkinson's Australia and Neuroscience Trials Australia could enhance patient recruitment.
Additionally, there are no significant trading trends from hedge funds or insiders, and the technical indicators suggest a bearish trend.
In Q3 2025, the company reported a net loss of $4.59 million, a 425.18% decline YoY. Revenue dropped to zero (-100% YoY), and EPS fell to -0.44 (-438.46% YoY). Gross margin remained at 100%, but this is not indicative of operational strength given the absence of revenue.
No data available for analyst ratings or price target changes.
